Dr. Amy Madl is President and Senior Principal Health Scientist with Valeo Sciences, a scientific consulting firm which provides integrative, multi-disciplinary, and fit-for-purpose scientific solutions to complex issues related to human health. Dr. Madl is board certified in toxicology, a Diplomate of the American Board of Toxicology (DABT),and has focused her academic and consulting experience in the field of inhalation toxicology. She has 25 years of experience in the sampling and analysis, toxicology, exposure, and risk assessment of airborne chemicals. Dr. Madl also holds a research position with the University of California, Davis, where her research interests have focused on the toxicological effects of inhaled nanoparticles (i.e., carbon nanotubes) and electronic nicotine delivery system (ENDS) products. She has served as co-investigator on multidisciplinary research teams for inhalation research studies funded by the NIEHS, University of California Toxic Substances Research & Teaching Program, and Tobacco Related Disease Research Program. Dr. Madl has led interdisciplinary research programs with the mission to integrate material physiochemistry, toxicology and hazard evaluation, and exposure science to characterize human health risk and public health impacts. Dr. Madl’s academic and consulting research of nicotine products has involved physiochemistry, toxicology, consumer exposures, pharmacokinetic and topography studies, and human health risk assessments. Dr. Madl has published over 120 abstracts, book chapters, and peer-reviewed papers on various exposure, toxicology, and risk-related topics, including issues involving chemical exposures in occupational, environmental, medical device, and consumer product scenarios.
